Mitochondrial Lipid Metabolism Genes as Diagnostic and Prognostic Indicators in Hepatocellular Carcinoma

Author:

Li Xuejing12,Tan Ying12,Liu Bihan2,Guo Houtian3,Zhou Yongjian3,Yuan Jianhui12,Wang Feng243

Affiliation:

1. Department of Physiology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China

2. Research Center for Biomedical Photonics, Institute of Life Science, Guangxi Medical University, Nanning, China

3. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China

4. Key Laboratory of Biological Molecular Medicine Research, Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China

Abstract

Background: Due to the heterogeneity of Hepatocellular carcinoma (HCC), there is an urgent need for reliable diagnosis and prognosis. Mitochondria-mediated abnormal lipid metabolism affects the occurrence and progression of HCC. Objective: This study aims to investigate the potential of mitochondrial lipid metabolism (MTLM) genes as diagnostic and independent prognostic biomarkers for HCC. Methods: MTLM genes were screened from the Gene Expression Omnibus (GEO) and Gene Set Enrichment Analysis (GSEA) databases, followed by an evaluation of their diagnostic values in both The Cancer Genome Atlas Program (TCGA) and the Affiliated Cancer Hospital of Guangxi Medical University (GXMU) cohort. The TCGA dataset was utilized to construct a gene signature and investigate the prognostic significance, immune infiltration, and copy number alterations. The validity of the prognostic signature was confirmed through GEO, International Cancer Genome Consortium (ICGC), and GXMU cohorts. Results: The diagnostic receiver operating characteristic (ROC) curve revealed that eight MTLM genes have excellent diagnostic of HCC. A prognostic signature comprising 5 MTLM genes with robust predictive value was constructed using the lasso regression algorithm based on TCGA data. The results of the Stepwise regression model showed that the combination of signature and routine clinical parameters had a higher area under the curve (AUC) compared to a single risk score. Further, a nomogram was constructed to predict the survival probability of HCC, and the calibration curves demonstrated a perfect predictive ability. Finally, the risk score also unveiled the different immune and mutation statuses between the two different risk groups. Conclusion: MTLT-related genes may serve as diagnostic and prognostic biomarkers for HCC as well as novel therapeutic targets, which may be beneficial for facilitating further understanding the molecular pathogenesis and providing potential therapeutic strategies for HCC.

Funder

Natural Science Foundation of China

Natural Science Foundation of Guangxi in China

Project of Improving the Basic Research Ability of Young and Middle-aged Teachers in Guangxi Universities

Publisher

Bentham Science Publishers Ltd.

Subject

Genetics (clinical),Genetics

Reference57 articles.

1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249

2. Petrick J.L.; Florio A.A.; Znaor A.; Ruggieri D.; Laversanne M.; Alvarez C.S.; Ferlay J.; Valery P.C.; Bray F.; McGlynn K.A.; International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer 2020,147(2),317-330

3. Craig A.J.; von Felden J.; Garcia-Lezana T.; Sarcognato S.; Villanueva A.; Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020,17(3),139-152

4. Zhou J.; Sun H.; Wang Z.; Cong W.; Wang J.; Zeng M.; Zhou W.; Bie P.; Liu L.; Wen T.; Han G.; Wang M.; Liu R.; Lu L.; Ren Z.; Chen M.; Zeng Z.; Liang P.; Liang C.; Chen M.; Yan F.; Wang W.; Ji Y.; Yun J.; Cai D.; Chen Y.; Cheng W.; Cheng S.; Dai C.; Guo W.; Hua B.; Huang X.; Jia W.; Li Y.; Li Y.; Liang J.; Liu T.; Lv G.; Mao Y.; Peng T.; Ren W.; Shi H.; Shi G.; Tao K.; Wang W.; Wang X.; Wang Z.; Xiang B.; Xing B.; Xu J.; Yang J.; Yang J.; Yang Y.; Yang Y.; Ye S.; Yin Z.; Zhang B.; Zhang B.; Zhang L.; Zhang S.; Zhang T.; Zhao Y.; Zheng H.; Zhu J.; Zhu K.; Liu R.; Shi Y.; Xiao Y.; Dai Z.; Teng G.; Cai J.; Wang W.; Cai X.; Li Q.; Shen F.; Qin S.; Dong J.; Fan J.; Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020,9(6),682-720

5. Chan A.W.H.; Zhong J.; Berhane S.; Toyoda H.; Cucchetti A.; Shi K.; Tada T.; Chong C.C.N.; Xiang B.D.; Li L.Q.; Lai P.B.S.; Mazzaferro V.; García-Fiñana M.; Kudo M.; Kumada T.; Roayaie S.; Johnson P.J.; Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 2018,69(6),1284-1293

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3